Business / Finance

RSS

Aptuit sells Clinical Trials Supply business to Catalent Pharma Solutions

Aptuit announces the completion of the sale of the Clinical Trials Supply business to Catalent Pharma Solutions on February 17, 2012. Timothy C. Tyson, Chairman and CEO of Aptuit, LLC stated that Aptuit will continue to deliver scientific and service excellence to provide integrated capabilities for the early to mid phase drug development markets.

18 Feb 2012

Meda's 2011 group net sales increase 18% to SEK 12,856 million

MEDA: Group net sales reached SEK 12,856 million (11,571). At fixed currency rates, sales increased 18%.

18 Feb 2012

Netsmart chooses Overland Park as the location for permanent Kansas office

Netsmart, the leading provider of clinical solutions for health and human services organizations nationwide, today announced it has selected 4950 College Boulevard, Overland Park, Kan., as the location for its permanent Kansas office. Netsmart has named the office the Solutionarium.

18 Feb 2012

Zhejiang Hisun Pharmaceutical, Pfizer sign framework agreement

Pfizer Inc. and Zhejiang Hisun Pharmaceutical, a leading pharmaceutical company in China, today signed a framework agreement, advancing their previously announced memorandum of understanding (MOU) to establish a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

18 Feb 2012

Par Pharmaceutical acquires Edict

Par Pharmaceutical Companies, Inc. announced today that it has completed the acquisition of privately-held Edict Pharmaceuticals Private Limited, an India-based developer and manufacturer of generic pharmaceuticals.

18 Feb 2012

Chemed declares 163rd consecutive quarterly dividend

Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.

18 Feb 2012

Ventas 2011 normalized FFO increases 71.1% to $777.0 million

Ventas, Inc. said today that normalized Funds From Operations for the year ended December 31, 2011 increased approximately 71.1 percent to $777.0 million, from $454.0 million for the comparable 2010 period.

18 Feb 2012

Abbott increases quarterly common dividend to 51 cents per share

The board of directors of Abbott today increased the company's quarterly common dividend from 48 cents per share to 51 cents per share.

18 Feb 2012

LifePoint Hospitals fourth quarter revenues increase 6.6% to $781.3M

LifePoint Hospitals, Inc. today announced results for the fourth quarter and year ended December 31, 2011.

18 Feb 2012

Alexza prices underwritten public offering of 44,000,000 shares of common stock and warrants

Alexza Pharmaceuticals, Inc., or the Company, today announced that it has priced its previously announced underwritten public offering of 44,000,000 shares of common stock and warrants to purchase 44,000,000 shares of common stock.

17 Feb 2012

HMS fourth quarter revenue increases 14.3% to $99.7 million

HMS Holdings Corp. today announced financial results for its fourth quarter and full year ended December 31, 2011.

17 Feb 2012

Pharmos reports net loss of $0.4 million for fourth quarter 2011

Pharmos Corporation reported financial results for the fourth quarter and twelve-month period ended December 31, 2011. These results are included in the Company's Yearly Report on Form 10-K which has been filed with the SEC.

17 Feb 2012

CryoPort announces closure of $5.0M private placement

CryoPort, Inc. today announced it has closed a private placement with various accredited investors for gross proceeds of $5.0 million. The Company obtained agreements to purchase 9,119,100 shares of common stock at $0.55 per share.

17 Feb 2012

Greatbatch acquires NeuroNexus

Greatbatch, Inc., today announced the acquisition of NeuroNexus Technologies for approximately $12 million in cash, including the assumption of debt and future considerations.

17 Feb 2012

Amerigroup reports net income of $32.8M for fourth quarter 2011

Amerigroup Corporation today announced that net income for the fourth quarter of 2011 was $32.8 million, or $0.67 per diluted share, versus $48.1 million, or $0.96 per diluted share, for the third quarter of 2011.

17 Feb 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

HeartWare revenues for fiscal 2011 increase to $82.8 million

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced revenue of $23.1 million for the fourth quarter ended December 31, 2011, as compared to $20.9 million for the fourth quarter of 2010.

16 Feb 2012